• 1
    Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Yu EB, et al.Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the EDUCATE trial.J Drugs Dermatol2007;6:299306.
  • 2
    Husted JA, Gladman DD, Farewell VT, Cook RJ.Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis.Arthritis Rheum2001;45:1518.
  • 3
    Sokoll KB, Helliwell PS.Comparison of disability and quality of life in rheumatoid and psoriatic arthritis.J Rheumatol2001;28:18426.
  • 4
    Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK.Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.Arthritis Rheum1984;27:86472.
  • 5
    Wolfe F, Hawley DJ.The longterm outcomes of rheumatoid arthritis. Work disability: a prospective 18 year study of 823 patients.J Rheumatol1998;25:210817.
  • 6
    Yelin E, Henke C, Epstein W.The work dynamics of the person with rheumatoid arthritis.Arthritis Rheum1987;30:50712.
  • 7
    Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, et al.Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.Ann Rheum Dis2012;71:114350.
  • 8
    Donahue KE, Jonas D, Hansen RA, Roubey R, Jonas B, Lux LJ, et al.Drug therapy for psoriatic arthritis in adults: update of a 2007 report.Rockville (MD):Agency for Healthcare Research and Quality;2012.
  • 9
    Emery P, Gabay C, Kraan M, Gomez-Reino J.Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.Rheumatol Int2007;27:793806.
  • 10
    Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al.Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study.Ann Rheum Dis2009;68:78996.
  • 11
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al.Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four–week efficacy and safety results of a randomized, placebo-controlled study.Arthritis Rheum2009;60:97686.
  • 12
    Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al.Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.Arthritis Rheum2008;58:340212.
  • 13
    Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, et al.Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.Arthritis Rheum2012;64:250417.
  • 14
    Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, et al.Clinical efficacy, radiographic, and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomized, placebo-controlled, GO-REVEAL study.Ann Rheum Dis2012. E-pub ahead of print.
  • 15
    Fries JF, Spitz P, Kraines RG, Holman HR.Measurement of patient outcome in arthritis.Arthritis Rheum1980;23:13745.
  • 16
    Mease PJ, Antoni CE, Gladman DD, Taylor WJ.Psoriatic arthritis assessment tools in clinical trials.Ann Rheum Dis2005;64 Suppl:ii4954.
  • 17
    Mease PJ, Woolley JN, Bitman B, Wang BC, Globe DR, Singh A.Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction.J Rheumatol2011;38:24615.
  • 18
    Ware JE Jr, Sherbourne CD.The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection.Med Care1992;30:47383.
  • 19
    Strand SV, Singh JA.Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.Am J Manag Care2008;14:23454.
  • 20
    Fredriksson T, Pettersson U.Severe psoriasis: oral therapy with a new retinoid.Dermatologica1978;157:23844.
  • 21
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al.American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis.Arthritis Rheum1995;38:72735.
  • 22
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis Rheum1995;38:448.
  • 23
    Castrejon I, Ortiz AM, Toledano E, Castaneda S, Garcia-Vadillo A, Patino E, et al.Estimated cutoff points for the 28-joint Disease Activity Score based on C-reactive protein in a longitudinal register of early arthritis.J Rheumatol2010;37:143943.
  • 24
    Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van der Tempel H, Mielants H, et al.Assessment of enthesitis in ankylosing spondylitis.Ann Rheum Dis2003;62:12732.
  • 25
    Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, et al.Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.Ann Rheum Dis2006;65:4717.
  • 26
    Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W.The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.Health Qual Life Outcomes2009;7:25.
  • 27
    Van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et al.Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.Arthritis Rheum2006;55:56974.
  • 28
    Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, et al.Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis.J Rheumatol2006;33:22549.
  • 29
    Revicki D, Roy S, Kimel M, Thompson C, Cifaldi M.Validation of the work performance visual analog scale: measuring work and household productivity of patients with early, aggressive rheumatoid arthritis [abstract].Arthritis Rheum2010;62 Suppl:S37.